PARP Inhibitors: — How a BRCA Mutation Becomes a Treatment Advantage

No. A BRCA mutation raises your lifetime risk substantially, but it is a risk factor, not a certainty. NCCN reports lifetime breast cancer risk for BRCA1 carriers in the range of 55 to 72 percent — which also means a meaningful proportion of carriers do not develop breast cancer at all, particularly those who undergo regular surveillance and consider risk-reduction steps. Knowing about the mutation early is what makes a concrete plan possible, and that is the part that is in your control.

A germline mutation is one you were born with. It is present in every cell in your body, it was inherited from a parent, and it can be passed to your children. A somatic mutation developed only in the tumour — it was not present at birth and is not heritable. Both can affect your eligibility for PARP inhibitors, but their implications for your family are completely different. If your result says germline, your first-degree relatives each have a one-in-two chance of carrying the same mutation and should be offered testing. If it says somatic, that concern does not apply in the same way.

Germline testing is done on a blood or saliva sample. In India, NCCN and ICMR guidance recommends testing for people with a personal or family history of breast cancer diagnosed under 50, ovarian cancer at any age, male breast cancer, bilateral breast cancer, or multiple cancers in close relatives on one side of the family. Results take two to four weeks and should always be reviewed with a genetic counsellor who can explain what the finding means for you and for your family members.

PARP inhibitors are prescribed and monitored at CION centres. Because they are oral tablets taken at home, most of your treatment does not require daily attendance at a clinic — but your team will schedule regular blood tests and review appointments to monitor side effects and assess response. Response-assessment scans including PET-CT are coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy; if that has been discussed as an option for you, you would be referred to a centre that offers it.

Each first-degree relative of someone with a germline BRCA mutation — a parent, sibling or child — has a one-in-two chance of carrying the same mutation. That applies regardless of your sex. Male carriers face elevated risks of their own, including prostate cancer and a raised risk of male breast cancer, and they can pass the mutation to their children. The only way to know whether you have inherited it is to be tested. Finding out early means you can start structured surveillance and consider risk-reduction steps before cancer develops.

In some settings they are, and in others they are used alone as maintenance therapy — meaning after an initial treatment has reduced the cancer's burden. The combination and maintenance approaches have different goals and different evidence bases. Which applies to you depends on your cancer type, stage and treatment history. PARP inhibitors are also being studied alongside immunotherapy in clinical trials, though that remains investigational in most settings. Your oncologist will explain the specific approach being recommended and what it is intended to achieve.